Area of research
Pulmonary and Respiratory Medicine · Pediatrics, Perinatology and Child Health
Research interest
Research interests include Sarcoma Diagnosis and Treatment, Childhood Cancer Survivors' Quality of Life, Neuroblastoma Research and Treatments, and Testicular diseases and treatments.
Impact of location of inpatient cancer care on patients with Ewing sarcoma and osteosarcoma—A population‐based study
Phase I Escalation and Expansion Study of Bemarituzumab (FPA144) in Patients With Advanced Solid Tumors and FGFR2b-Selected Gastroesophageal Adenocarcinoma
Results of a Randomized, Double-Blinded, Placebo-Controlled, Phase 2.5 Study of Saracatinib (AZD0530), in Patients with Recurrent Osteosarcoma Localized to the Lung
Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort
High-Dose Chemotherapy Compared With Standard Chemotherapy and Lung Radiation in Ewing Sarcoma With Pulmonary Metastases: Results of the European Ewing Tumour Working Initiative of National Groups, 99 Trial and EWING 2008
Bemarituzumab With Modified Folfox6 For Advanced Fgfr2-Positive Gastroesophageal Cancer: Fight Phase Iii Study Design
Effects of dexrazoxane on doxorubicin-related cardiotoxicity and second malignant neoplasms in children with osteosarcoma: a report from the Children’s Oncology Group
Phase 1a/1b study of first-in-class B7-H4 antibody, FPA150, as monotherapy in patients with advanced solid tumors.
Genome-Informed Targeted Therapy for Osteosarcoma
Longitudinal follow‐up of adult survivors of Ewing sarcoma: A report from the Childhood Cancer Survivor Study
How to Provide Gadolinium-Free PET/MR Cancer Staging of Children and Young Adults in Less than 1 h: the Stanford Approach
Mortality in young adults with Ewing sarcoma treated at specialized cancer centers in California.
Complete dexrazoxane cardioprotection for cardiac function but incomplete female cardioprotection for cardiac structure in doxorubicin-treated osteosarcoma survivors: Hearts too small for the body.
Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial
Comparison of clinical features and outcomes in patients with extraskeletal versus skeletal localized Ewing sarcoma: A report from the Children's Oncology Group
Three-dimensional Radiologic Assessment of Chemotherapy Response in Ewing Sarcoma Can Be Used to Predict Clinical Outcome
Efficacy of busulfan-melphalan high dose chemotherapy consolidation (BuMel) compared to conventional chemotherapy combined with lung irradiation in ewing sarcoma (ES) with primary lung metastases: Results of EURO-EWING 99-R2pulm randomized trial (EE99R2pul).
Racial/ethnic and socioeconomic disparities in survival among children with acute lymphoblastic leukemia in California, 1988-2011: A population-based observational study
Identification of Discrete Prognostic Groups in Ewing Sarcoma
Age, Tumor Characteristics, and Treatment Regimen as Event Predictors in Ewing: A Children’s Oncology Group Report
Longitudinal evaluation of health status and chronic conditions in aging pediatric astrocytoma survivors: A Childhood Cancer Survivor Study (CCSS) report.
EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment
Comparative evaluation of local control strategies in localized Ewing sarcoma of bone: A report from the Children's Oncology Group
Symptom Assessment in Pediatric Oncology
Tumoral <i>TP53</i> and/or <i>CDKN2A</i> alterations are not reliable prognostic biomarkers in patients with localized Ewing sarcoma: A report from the Children's Oncology Group
Genome-wide association study identifies two susceptibility loci for osteosarcoma
Feasibility and dose discovery analysis of zoledronic acid with concurrent chemotherapy in the treatment of newly diagnosed metastatic osteosarcoma: A report from the Children’s Oncology Group
Pilot study of cisplatin, etoposide, bleomycin, and escalating dose cyclophosphamide therapy for children with high risk germ cell tumors: A report of the children's oncology group (COG)
MAP plus maintenance pegylated interferon α-2b (MAP-IFN) versus MAP alone in patients (pts) with resectable high-grade osteosarcoma and good histologic response to preoperative MAP: First results of the EURAMOS-1 good response randomization.
MAP plus maintenance pegylated interferon α-2b (MAPIfn) versus MAP alone in patients with resectable high-grade osteosarcoma and good histologic response to preoperative MAP: First results of the EURAMOS-1 “good response” randomization.